successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type ii
Clics: 241
ID: 191268
2015
Metricas de Calidad y Rendimiento del Articulo
Calidad General
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Participacion del Lector
Popular Article
30.0
/100
241 vistas
36 lectores
Evaluacion de Calidad por IA
No analizado
Readership in this journal
PopularRanked #26 of 57 articles by views in advances in skin & wound care
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Resumen
We report on a 6 year old boy with severe MPS II undergoing immune modulation therapy due to high IgG antibody titers to IV idursulfase and no significant decline in urinary GAG levels since initiating enzyme replacement therapy. He has complete deficiency of iduronate-2-sulfatase activity due to a submicroscopic deletion of the X chromosome involving the entire I2S gene but not including in the fragile X locus. At 19 months of age, IV idursulfase therapy at the recommended dose of 0.5 mg/kg/week was initiated and then increased to 1.0 mg/kg/week after no observed clinical improvement and no decline in urine GAG level. After one year of ERT at the increased dose, he had no significant decline in urinary GAG excretion and increase of anti-idursulfase IgG antibody titers to 102,000 with complete neutralizing antibodies. In light of the evidence of lack of efficacy of idursulfase therapy, the patient was started on an immune modulation regimen consisting of ofatumumab, bortezomib, methotrexate and IVIG for a 12 week period. Only a slight decrease in IgG titers and urine GAG levels was observed, leading to increased intensity of bortezomib administration and addition of dexamethasone to the regimen, while continuing with the current schedule ofatumumab, IVIG and methotrexate. Over 18 month period of immune modulation therapy, we observed a significant reduction in anti-idursulfase IgG titers and a moderate reduction in urine GAG levels compared to baseline. Modest clinical improvements were observed. Our experience suggests that future MPS II patients with a complete gene deletion may be likely to develop persistent anti-idursulfase antibody titers and may benefit from immune modulation therapy prior to the development of high titer levels.
| Clave de Referencia |
kim2015molecularsuccessful
Use esta clave para autocitar en el manuscrito mientras usa
SciMatic Manuscript Manager o Thesis Manager
|
|---|---|
| Autores | ;Katherine H. Kim;Yoav H. Messinger;Barbara K. Burton |
| Revista | advances in skin & wound care |
| Ano | 2015 |
| DOI |
10.1016/j.ymgmr.2014.11.007
|
| URL | |
| Palabras Clave |
Citas
No se encontraron citas. Para agregar una cita, contacte al administrador en info@scimatic.org
Comentarios
Aun no hay comentarios. Sea el primero en comentar este articulo.